比较地加瑞克和戈舍瑞林的有效性和安全性的试验后实施的关于地加瑞克的扩展长期安全性和耐受性试验
[Translation] Extended long-term safety and tolerability trial of degarelix following a trial comparing the efficacy and safety of degarelix and goserelin
评价地加瑞克一个月给药方案对于中国前列腺癌患者在长期治疗过程中的安全性和耐受性
[Translation] To evaluate the safety and tolerability of a one-month dosing regimen of degarelix in Chinese patients with prostate cancer during long-term treatment
一项开放性、多中心、随机、平行对照的研究,比较地加瑞克与戈舍瑞林对前列腺癌患者的有效性与安全性
[Translation] An open-label, multicenter, randomized, parallel-controlled study comparing the efficacy and safety of degarelix and goserelin in patients with prostate cancer
验证地加瑞克(240/80mg)每月一次给药方案和戈舍瑞林相比,首次用药后第2天起至第364 天止降低并维持睾酮于去势水平(≤0.5 ng/mL)的非劣性
[Translation] Validation of degarelix (240/80mg) once-monthly dosing regimen compared with goserelin to reduce and maintain testosterone at castration levels (≤0.5 ng/mL) from day 2 to day 364 after the first dose non-inferiority
100 Clinical Results associated with Rentschler Biotechnologie Beteiligungs Gmbh
0 Patents (Medical) associated with Rentschler Biotechnologie Beteiligungs Gmbh
100 Deals associated with Rentschler Biotechnologie Beteiligungs Gmbh
100 Translational Medicine associated with Rentschler Biotechnologie Beteiligungs Gmbh